Ocular’s OTX-DED Succeeds In Dry Eye Where OTX-CSI Failed, But More Data Needed
The Phase II trial showed significant improvement in eye redness in patients with dry eye disease, but additional data are needed on DED symptom improvement.
You may also be interested in...
The firm’s lead asset, reproxalap, one-upped Novartis’s Xiidra in a mid-stage ophthalmology study, signalling its first-line promise in a market ridden with compliance issues.
Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.
Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.